Important Update on FDA Changes Concerning Peptides BPC 157: Experimental Peptide Creates Risk for Athletes Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance[v3] Preprints.org Is BPC 157 Legal? Understanding Its Status and Implications The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York